Skip to content
  • Diagnosis
  • Treatment
  • Patient Management
  • Patient Resources
  • Events
  • Contributors
  • Diagnosis
  • Treatment
  • Patient Management
  • Patient Resources
  • Events
  • Contributors
  • Diagnosis
  • Treatment
  • Patient Management
  • Patient Resources
  • Events
  • Contributors
  • Diagnosis
  • Treatment
  • Patient Management
  • Patient Resources
  • Events
  • Contributors

Category: Patient Management

Prevalence and Risk Factors of Tardive Dyskinesia in Patients With Schizophrenia on Antipsychotics

A recent study explored the prevalence and risk factors for tardive dyskinesia (TD) in patients with schizophrenia undergoing long-term antipsychotic treatment. It found that 35.9% of patients exhibited TD symptoms, with older age, Chinese ethnicity, and prolonged antipsychotic use being significant risk factors.

Higher Antipsychotic Doses Tied to Increased Risk of Tardive Dyskinesia

Tardive dyskinesia (TD) is a serious, often irreversible movement disorder caused by long-term use of dopamine receptor antagonists, particularly antipsychotics.

Clarifying the Language of Tardive Syndromes: A Call for Consistency in Diagnosis and Care

Tardive dyskinesia (TD) was first identified in the 1950s as involuntary oral and facial movements linked to prolonged chlorpromazine use.

Neuroinflammation Implicated in Tardive Dyskinesia Pathogenesis

Emerging research suggests that immune system dysregulation may play a role in the development of tardive dyskinesia (TD), a movement disorder linked to long-term use of dopamine receptor-blocking antipsychotics.

The Tardive Dyskinesia Impact Scale: A Comprehensive Measure of TD’s Impact from the Patient Perspective

Tardive dyskinesia (TD) significantly impacts patients’ physical, cognitive, and psychosocial functioning. The Abnormal Involuntary Movement Scale (AIMS) is commonly used to evaluate TD treatment efficacy in clinical trials but does not capture the patient perspective on the impacts of uncontrolled movements.

Social Media Listening Reveals Emotional and Social Challenges of Tardive Dyskinesia in Patients and Caregivers

This pilot study aimed to use social media listening (SML) to gain insights into the patient and caregiver experiences of tardive dyskinesia (TD), a movement disorder associated with prolonged use of dopamine receptor-blocking agents like antipsychotics.

Impact of Tardive Dyskinesia on Caregivers: Strain on Well-Being, Work, and Daily Life

This study examines the impact of tardive dyskinesia (TD) on informal caregivers, focusing on their physical, psychological, and social well-being. Surveys of 162 caregivers revealed that TD significantly affects caregivers’ daily activities, professional lives, and mental health.

Improving Tardive Dyskinesia Management in Japan: Prevention, Diagnosis, and New Treatments

Tardive dyskinesia (TD) is underrecognized in Japan, partly due to cultural stigma and limited awareness among healthcare professionals. Early diagnosis is challenging, as TD may resemble other movement disorders, and it is often irreversible.

Managing Tardive Dyskinesia: A Case Study Highlighting Diagnosis, Treatment, and Prevention Strategies

The pathophysiology of tardive dyskinesia (TD) involves prolonged dopamine receptor blockade, leading to receptor supersensitivity and oxidative damage in the striatum.

Expert Panel: Routine Impact Assessments Key to Managing Tardive Dyskinesia

Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary movements that significantly affect physical, cognitive, and psychosocial functioning.

Next →
Privacy Policy
Your Privacy Choices
Terms of Use
Company
Contact
Partner with Us
Ambassador Program

© 2025 POCN—an IQVIA business. All Rights Reserved.